未分类自身炎症性疾病的全外显子组测序:更多单基因病待发现?
本研究对11例来自儿科风湿免疫科的未分类自身炎症性疾病(AID)患者先筛查MEFV,再行全外显子组测序(WES)。WES在4/11例(36%)中提供确定或可能致病变异,涉及ADAM17、TBK1、LIG4、RAG1,并提出NLRC3为强候选基因。作者认为WES对选定未定义AID患者具有成本效益并可提供实质结果。
要点
- 对常见AID panel未确诊的患儿,WES可提高遗传诊断率。
- WES在4/11例(36%)中提供确定或可能致病变异。
- ADAM17、TBK1、LIG4、RAG1及候选NLRC3拓展了未分类AID的基因谱。
核心结论
- WES策略对一组选定的未定义AID患者具有成本效益并可提供实质结果。
- 本研究结果将有助于拓展未分类AID的疾病谱。
研究设计与样本
- 研究纳入在Hacettepe大学儿科风湿免疫科随访、具有AID特征的患者。
- 患者先以Sanger测序筛查MEFV,临床意义不显著者再行WES。
- WES数据预分析考虑13个最常见AID相关基因,仍未确诊者进一步行生物信息学分析。
- 共11例患者纳入分析。
主要发现
- WES在4/11例患者(36%)中提供确定或可能致病变异。
- 其中两个基因的杂合突变既往与神经缺陷相关(ADAM17、TBK1),且在一个新生儿炎症性皮肤与肠道病家系中观察到ADAM17纯合突变。
- LIG4、RAG1两个基因与免疫缺陷相关,尽管患者以炎症特征就诊。
- 对一例患者,将强候选基因NLRC3与自身炎症特征相关联。
- 疾病起病中位年龄1.2岁(范围0.2-16),研究招募时中位年龄14岁(范围3.5-17)。
关键数值与推荐
- WES在11例未分类AID患者中4例(36%)提供确定或可能致病变异。
- WES预分析覆盖13个最常见AID相关基因。
- 疾病起病中位年龄1.2岁(范围0.2-16),招募时中位年龄14岁(范围3.5-17)。
临床怎么用
- 对常见AID基因panel未确诊、临床高度怀疑单基因AID的患者,可考虑WES。
- WES分析应先关注常见AID相关基因,未确诊时再扩展生物信息学分析。
- 对以炎症特征就诊者,需留意LIG4、RAG1等免疫缺陷相关基因。
- ADAM17、TBK1、NLRC3等结果可提示向神经缺陷、免疫缺陷及自身炎症表型扩展评估。
局限性
- 样本量小(11例),结论外推需谨慎。
- NLRC3仅为强候选基因关联,未确立致病性。
- 部分变异为可能致病,并非全部确定致病。
- 研究为单中心儿科风湿免疫队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoinflammatory diseases (AIDs) are characterized by recurrent sterile systemic inflammation attacks. More than half of the patients remain genetically undiagnosed with next-generation sequencing panels for common AIDs. In this study, we aimed to define phenotype-genotype correlations in a cohort of unclassified AID patients via whole exome sequencing (WES). METHODS: Patients with features of AIDs were included in this study followed in the Department of Pediatric Rheumatology at Hacettepe University. They were first screened for MEFV with Sanger sequencing and then WES performed for the patients with clinically insignificant results. Pre-analysis of WES data was done by considering the 13 most common AID-related genes. Further bioinformatic analysis was performed if the patient remained genetically undiagnosed. RESULTS: The median age at disease onset was 1.2 years (range 0.2-16) and at the time of study recruitment was 14 years (range 3.5-17). In our cohort, WES provided a definite or probable disease-causing variant in 4 of 11 patients (36%). Heterozygous mutations for two of these genes were previously associated with neurological defects (ADAM17, TBK1), also homozygous ADAM17 mutations were observed in one family with neonatal inflammatory skin and bowel disease. Besides, two genes (LIG4, RAG1) were associated with immunodeficiency although the patients had presented with inflammatory features. Finally, for one patient, we associated a strong candidate gene (NLRC3) with autoinflammatory features. CONCLUSION: WES strategy is cost-effective and provides substantial results for a selected group of undefined AID patients. Our results will contribute to the spectrum of unclassified AIDs.
引用
- Kosukcu C, Taskiran EZ, Batu ED, et al. Whole exome sequencing in unclassified autoinflammatory diseases: more monogenic diseases in the pipeline? Rheumatology (Oxford). 2021. PMID: 32447396. doi:10.1093/rheumatology/keaa165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。